Vault-13

Venrock Adviser, LLC

NEW YORK, NY · CIK 1615982 · 13F filing filed 2023-05-15

SEC-registered investment adviser since 2014 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 11
Palo Alto, CAUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$507.8m reported value -17.7% vs Q1 2022
27positions
74.1%in top 10
7 new 6 added 5 reduced 7 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 TRICIDA INC COM TCDA TCDA 7,132,079 $69.0m13.60% 13.60% AddedShares held: Q3 2021 390.7k, Q4 2021 3.5m, Q1 2022 4.5m, Q2 2022 7.1m +2.6m +2,637,228 58.7%
2 ACLARIS THERAPEUTICS INC COM ACRS ACRS 4,563,962 $63.7m12.55% 12.55% UnchangedShares held: Q3 2021 4.6m, Q4 2021 4.6m, Q1 2022 4.6m, Q2 2022 4.6m
3 RELMADA THERAPEUTICS INC COM RLMD RLMD 2,270,072 $43.1m8.49% 8.49% UnchangedShares held: Q3 2021 1.4m, Q4 2021 2.3m, Q1 2022 2.3m, Q2 2022 2.3m
4 TRAVERE THERAPEUTICS INC COM TVTX TVTX 1,711,102 $41.5m8.17% 8.17% ReducedShares held: Q3 2021 1.7m, Q4 2021 2.0m, Q1 2022 2.0m, Q2 2022 1.7m -283.9k -283,895 -14.2%
5 COGENT BIOSCIENCES INC COM COGT COGT 4,038,117 $36.4m7.17% 7.17% AddedShares held: Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 1.1m, Q2 2022 4.0m +2.9m +2,949,300 270.9%
6 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 3,185,573 $31.8m6.26% 6.26% AddedShares held: Q3 2021 1.6m, Q4 2021 2.0m, Q1 2022 2.1m, Q2 2022 3.2m +1.1m +1,134,513 55.3%
7 INSTIL BIO INC COM COM 5,997,657 $27.7m5.46% 5.46% ReducedShares held: Q3 2021 6.9m, Q4 2021 6.9m, Q1 2022 6.9m, Q2 2022 6.0m -867.4k -867,419 -12.6%
8 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 865,116 $23.3m4.59% 4.59% UnchangedShares held: Q3 2021 1.1m, Q4 2021 865.1k, Q1 2022 865.1k, Q2 2022 865.1k
9 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 1,852,919 $21.4m4.22% 4.22% UnchangedShares held: Q3 2021 19.5k, Q4 2021 1.9m, Q1 2022 1.9m, Q2 2022 1.9m
10 VISTAGEN THERAPEUTICS INC COM NEW VTGN VTGN 20,697,286 $18.2m3.59% 3.59% AddedShares held: Q3 2021 16.0m, Q4 2021 16.0m, Q1 2022 16.0m, Q2 2022 20.7m +4.7m +4,650,000 29.0%
11 MARINUS PHARMACEUTICALS INC COM NEW MRNS MRNS 3,156,803 $15.3m3.01% 3.01% UnchangedShares held: Q3 2021 2.6m, Q4 2021 2.9m, Q1 2022 3.2m, Q2 2022 3.2m
12 AADI BIOSCIENCE INC COM WHWK WHWK 1,173,518 $14.5m2.85% 2.85% ReducedShares held: Q3 2021 1.5m, Q4 2021 1.5m, Q1 2022 1.5m, Q2 2022 1.2m -355.9k -355,884 -23.3%
13 INOZYME PHARMA INC COM COM 2,709,987 $12.9m2.55% 2.55% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.7m
14 AKOUOS INC COM COM 2,667,119 $12.5m2.46% 2.46% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.7m
15 LIANBIO SPONSORED ADS LIANY LIANY 5,378,341 $11.6m2.29% 2.29% UnchangedShares held: Q3 2021 0, Q4 2021 5.4m, Q1 2022 5.4m, Q2 2022 5.4m
16 AEROVATE THERAPEUTICS INC COM COM 590,408 $9.2m1.82% 1.82% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 151.0k, Q2 2022 590.4k +439.4k +439,371 290.9%
17 TREVI THERAPEUTICS INC COM TRVI TRVI 3,050,022 $8.6m1.69% 1.69% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 3.1m
18 CHINOOK THERAPEUTICS INC COM ADRO ADRO 489,618 $8.6m1.69% 1.69% ReducedShares held: Q3 2021 0, Q4 2021 1.3m, Q1 2022 1.3m, Q2 2022 489.6k -794.2k -794,203 -61.9%
19 ANNEXON INC COM ANNX ANNX 1,928,477 $7.3m1.43% 1.43% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.9m
20 SAVARA INC COM SVRA SVRA 4,117,530 $6.3m1.23% 1.23% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 1.9m, Q2 2022 4.1m +2.2m +2,212,265 116.1%
21 LYRA THERAPEUTICS INC COM LYRA LYRA 924,170 $5.2m1.03% 1.03% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 924.2k
22 PROVENTION BIO INC COM PRVB PRVB 1,118,653 $4.5m0.88% 0.88% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 1.1m, Q2 2022 1.1m
23 ALTIMMUNE INC COM NEW ALT ALT 369,306 $4.3m0.85% 0.85% ReducedShares held: Q3 2021 3.8m, Q4 2021 0, Q1 2022 759.7k, Q2 2022 369.3k -390.4k -390,413 -51.4%
24 ATYR PHARMA INC COM NEW ATYR ATYR 1,398,889 $4.0m0.78% 0.78% UnchangedShares held: Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.4m, Q2 2022 1.4m
25 AFFIMED N V COM COM 1,428,571 $4.0m0.78% 0.78% UnchangedShares held: Q3 2021 0, Q4 2021 1.4m, Q1 2022 1.4m, Q2 2022 1.4m
26 RALLYBIO CORP COM COM 268,532 $2.0m0.40% 0.40% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 268.5k
27 XENON PHARMACEUTICALS INC COM XENE XENE 30,000 $913.0k0.18% 0.18% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 30.0k

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
ATHIRA PHARMA INC 1,000,000 $13.5m1.0m shares
EIGER BIOPHARMACEUTICALS INC CLDN CLDN 1,469,767 $12.2m1.5m shares
NUVALENT INC 803,951 $11.2m804.0k shares
GRAPHITE BIO INC GRPH GRPH 1,612,617 $8.2m1.6m shares
SIERRA ONCOLOGY INC 162,479 $5.2m162.5k shares
CENTESSA PHARMACEUTICALS PLC 411,361 $3.7m411.4k shares
ASTRIA THERAPEUTICS INC CATB CATB 538,999 $3.6m539.0k shares